Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion

Hyun Chang Ko, Woo Il Kim, Sang Hyun Cho, Young Lip Park, Eung Ho Choi, Sang Wook Son, Bark Lynn Lew, Yang Won Lee, Young Jun Seo, Gyong Moon Kim, Joon Hong Min, Chan Ho Na, Chong Hyun Won, Hyoseung Shin, Kwang Hoon Lee, Joo Young Roh, Young Min Park, Yong Hyun Jang, Seok Kweon Yun, You Chan Kim & 2 others Gyeong Hun Park, Chun Wook Park

Research output: Contribution to journalArticle

Abstract

Background: Topical tacrolimus is an effective anti-inflammatory therapy for acute and chronic states of atopic dermatitis (AD) in both adults and children. Topical tacrolimus has particular use at sensitive areas such as the face, anogenitals, and skin folds of neck and extremities. However, many AD patients also experience aggravated symptoms on trunk. Objective: The aim of this study was to investigate the efficacy and safety of topical tacrolimus for AD patients with truncal lesions. Methods: AD patients with truncal lesions who were aged ≥2 years were recruited from 20 centres in Korea. They received treatment with topical tacrolimus ointment twice daily during 4 weeks. The primary end point was change of the local eczema area and severity index (EASI) of the trunk from baseline to day 28. The secondary end points were changes in the patient global assessment (PGA) score and itch visual analogue scale (VAS) score of the trunk between baseline and day 28. Results: Two hundred and ninety-one patients were recruited, and 176 patients completed the full 4-week treatment course. By the end of the treatment, the mean local EASI of the trunk (2.2±4.71) was significantly decreased from that at baseline (4.71±4.03, p<0.001). PGA (1.71±1.15) and itch VAS score of the trunk (2.61±2.19) on day 28 were also profoundly decreased compared with the baseline (2.96±1.07 and 5.15±2.47, respectively). No serious adverse events were observed during the study period. Conclusion: Topical tacrolimus is an effective and safe therapy for truncal lesions in AD patients.

Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalAnnals of Dermatology
Volume30
Issue number2
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Tacrolimus
Atopic Dermatitis
Eczema
Therapeutics
Visual Analog Scale
Korea
Ointments
Anti-Inflammatory Agents
Neck
Extremities
Safety
Skin

Keywords

  • Atopic dermatitis
  • Tacrolimus
  • Topical administration

ASJC Scopus subject areas

  • Dermatology

Cite this

Ko, H. C., Kim, W. I., Cho, S. H., Park, Y. L., Choi, E. H., Son, S. W., ... Park, C. W. (2018). Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion. Annals of Dermatology, 30(2), 173-178. https://doi.org/10.5021/ad.2018.30.2.173

Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion. / Ko, Hyun Chang; Kim, Woo Il; Cho, Sang Hyun; Park, Young Lip; Choi, Eung Ho; Son, Sang Wook; Lew, Bark Lynn; Lee, Yang Won; Seo, Young Jun; Kim, Gyong Moon; Min, Joon Hong; Na, Chan Ho; Won, Chong Hyun; Shin, Hyoseung; Lee, Kwang Hoon; Roh, Joo Young; Park, Young Min; Jang, Yong Hyun; Yun, Seok Kweon; Kim, You Chan; Park, Gyeong Hun; Park, Chun Wook.

In: Annals of Dermatology, Vol. 30, No. 2, 01.04.2018, p. 173-178.

Research output: Contribution to journalArticle

Ko, HC, Kim, WI, Cho, SH, Park, YL, Choi, EH, Son, SW, Lew, BL, Lee, YW, Seo, YJ, Kim, GM, Min, JH, Na, CH, Won, CH, Shin, H, Lee, KH, Roh, JY, Park, YM, Jang, YH, Yun, SK, Kim, YC, Park, GH & Park, CW 2018, 'Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion', Annals of Dermatology, vol. 30, no. 2, pp. 173-178. https://doi.org/10.5021/ad.2018.30.2.173
Ko, Hyun Chang ; Kim, Woo Il ; Cho, Sang Hyun ; Park, Young Lip ; Choi, Eung Ho ; Son, Sang Wook ; Lew, Bark Lynn ; Lee, Yang Won ; Seo, Young Jun ; Kim, Gyong Moon ; Min, Joon Hong ; Na, Chan Ho ; Won, Chong Hyun ; Shin, Hyoseung ; Lee, Kwang Hoon ; Roh, Joo Young ; Park, Young Min ; Jang, Yong Hyun ; Yun, Seok Kweon ; Kim, You Chan ; Park, Gyeong Hun ; Park, Chun Wook. / Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion. In: Annals of Dermatology. 2018 ; Vol. 30, No. 2. pp. 173-178.
@article{2f4e83f0f142414bad25d067a47b74fb,
title = "Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion",
abstract = "Background: Topical tacrolimus is an effective anti-inflammatory therapy for acute and chronic states of atopic dermatitis (AD) in both adults and children. Topical tacrolimus has particular use at sensitive areas such as the face, anogenitals, and skin folds of neck and extremities. However, many AD patients also experience aggravated symptoms on trunk. Objective: The aim of this study was to investigate the efficacy and safety of topical tacrolimus for AD patients with truncal lesions. Methods: AD patients with truncal lesions who were aged ≥2 years were recruited from 20 centres in Korea. They received treatment with topical tacrolimus ointment twice daily during 4 weeks. The primary end point was change of the local eczema area and severity index (EASI) of the trunk from baseline to day 28. The secondary end points were changes in the patient global assessment (PGA) score and itch visual analogue scale (VAS) score of the trunk between baseline and day 28. Results: Two hundred and ninety-one patients were recruited, and 176 patients completed the full 4-week treatment course. By the end of the treatment, the mean local EASI of the trunk (2.2±4.71) was significantly decreased from that at baseline (4.71±4.03, p<0.001). PGA (1.71±1.15) and itch VAS score of the trunk (2.61±2.19) on day 28 were also profoundly decreased compared with the baseline (2.96±1.07 and 5.15±2.47, respectively). No serious adverse events were observed during the study period. Conclusion: Topical tacrolimus is an effective and safe therapy for truncal lesions in AD patients.",
keywords = "Atopic dermatitis, Tacrolimus, Topical administration",
author = "Ko, {Hyun Chang} and Kim, {Woo Il} and Cho, {Sang Hyun} and Park, {Young Lip} and Choi, {Eung Ho} and Son, {Sang Wook} and Lew, {Bark Lynn} and Lee, {Yang Won} and Seo, {Young Jun} and Kim, {Gyong Moon} and Min, {Joon Hong} and Na, {Chan Ho} and Won, {Chong Hyun} and Hyoseung Shin and Lee, {Kwang Hoon} and Roh, {Joo Young} and Park, {Young Min} and Jang, {Yong Hyun} and Yun, {Seok Kweon} and Kim, {You Chan} and Park, {Gyeong Hun} and Park, {Chun Wook}",
year = "2018",
month = "4",
day = "1",
doi = "10.5021/ad.2018.30.2.173",
language = "English",
volume = "30",
pages = "173--178",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "2",

}

TY - JOUR

T1 - Topical tacrolimus for the treatment of atopic dermatitis with truncal lesion

AU - Ko, Hyun Chang

AU - Kim, Woo Il

AU - Cho, Sang Hyun

AU - Park, Young Lip

AU - Choi, Eung Ho

AU - Son, Sang Wook

AU - Lew, Bark Lynn

AU - Lee, Yang Won

AU - Seo, Young Jun

AU - Kim, Gyong Moon

AU - Min, Joon Hong

AU - Na, Chan Ho

AU - Won, Chong Hyun

AU - Shin, Hyoseung

AU - Lee, Kwang Hoon

AU - Roh, Joo Young

AU - Park, Young Min

AU - Jang, Yong Hyun

AU - Yun, Seok Kweon

AU - Kim, You Chan

AU - Park, Gyeong Hun

AU - Park, Chun Wook

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Topical tacrolimus is an effective anti-inflammatory therapy for acute and chronic states of atopic dermatitis (AD) in both adults and children. Topical tacrolimus has particular use at sensitive areas such as the face, anogenitals, and skin folds of neck and extremities. However, many AD patients also experience aggravated symptoms on trunk. Objective: The aim of this study was to investigate the efficacy and safety of topical tacrolimus for AD patients with truncal lesions. Methods: AD patients with truncal lesions who were aged ≥2 years were recruited from 20 centres in Korea. They received treatment with topical tacrolimus ointment twice daily during 4 weeks. The primary end point was change of the local eczema area and severity index (EASI) of the trunk from baseline to day 28. The secondary end points were changes in the patient global assessment (PGA) score and itch visual analogue scale (VAS) score of the trunk between baseline and day 28. Results: Two hundred and ninety-one patients were recruited, and 176 patients completed the full 4-week treatment course. By the end of the treatment, the mean local EASI of the trunk (2.2±4.71) was significantly decreased from that at baseline (4.71±4.03, p<0.001). PGA (1.71±1.15) and itch VAS score of the trunk (2.61±2.19) on day 28 were also profoundly decreased compared with the baseline (2.96±1.07 and 5.15±2.47, respectively). No serious adverse events were observed during the study period. Conclusion: Topical tacrolimus is an effective and safe therapy for truncal lesions in AD patients.

AB - Background: Topical tacrolimus is an effective anti-inflammatory therapy for acute and chronic states of atopic dermatitis (AD) in both adults and children. Topical tacrolimus has particular use at sensitive areas such as the face, anogenitals, and skin folds of neck and extremities. However, many AD patients also experience aggravated symptoms on trunk. Objective: The aim of this study was to investigate the efficacy and safety of topical tacrolimus for AD patients with truncal lesions. Methods: AD patients with truncal lesions who were aged ≥2 years were recruited from 20 centres in Korea. They received treatment with topical tacrolimus ointment twice daily during 4 weeks. The primary end point was change of the local eczema area and severity index (EASI) of the trunk from baseline to day 28. The secondary end points were changes in the patient global assessment (PGA) score and itch visual analogue scale (VAS) score of the trunk between baseline and day 28. Results: Two hundred and ninety-one patients were recruited, and 176 patients completed the full 4-week treatment course. By the end of the treatment, the mean local EASI of the trunk (2.2±4.71) was significantly decreased from that at baseline (4.71±4.03, p<0.001). PGA (1.71±1.15) and itch VAS score of the trunk (2.61±2.19) on day 28 were also profoundly decreased compared with the baseline (2.96±1.07 and 5.15±2.47, respectively). No serious adverse events were observed during the study period. Conclusion: Topical tacrolimus is an effective and safe therapy for truncal lesions in AD patients.

KW - Atopic dermatitis

KW - Tacrolimus

KW - Topical administration

UR - http://www.scopus.com/inward/record.url?scp=85043291038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043291038&partnerID=8YFLogxK

U2 - 10.5021/ad.2018.30.2.173

DO - 10.5021/ad.2018.30.2.173

M3 - Article

VL - 30

SP - 173

EP - 178

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 2

ER -